accountAustralia-based Genetic Technologies Ltd. (GENE) advanced a step closer to marketing a genetic breast cancer test, and investors immediately drove the company’s stock up 85% at midday, when the stock was trading around $5.85.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Graphic Evidence: Genetic Technologies Soars on Cancer Test News
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account